Posted by & filed under Chronic Condition, Hemophilia, Infusion, Specialty Pharmacy, Uncategorized.

Hemlibra reduces bleeding episodes in hemophilia A patients with inhibitorsARJ_Patient_Enrollment_Form_Hemlibra


Genentech selected ARJ Infusion Services as one of its pharmacy partners based on our expertise and dedication to clinical excellence.

For nearly 20 years, ARJ has been a nationally recognized leader in delivering specialty pharmacy and nursing services to people with bleeding disorders and other complex genetic conditions. Our certified pharmacists and nurses specialize in customized infusion therapy, in-home nursing care, and on-site clinical treatments for adult and pediatric patients in all 50 ARJ_Infusion_Services_Call_Us_Intakestates.

Our team of clinicians treat children and adults with hemophilia, von Willebrand, and other inherited or acquired bleeding disorders.


Get to know ARJ

ARJ provides insurance coverage supportpatient assistance, and other infusion therapy solutions.

About Genentech’s Hemlibra

Genentech’s Hemlibra (emicizumab-kxwh) is a prescription medicine that can be self-administered subcutaneously to people with hemophilia A who have developed factor VIII inhibitors. As a prophylactic treatment, the highly anticipated drug has been shown to prevent or significantly reduce the frequency of bleeding episodes in children and adults who receive weekly injections.

Hemophilia A is a rare genetic bleeding disorder caused by a missing or defective blood-clotting protein called factor VIII. The absence of factor VIII can lead to prolonged bleeding episodes and result in serious joint damage.


Learn more

Before using Hemlibra, contact your primary physician to review your medical and prescription history.

Review important safety information about Genentech’s Hemlibra product.